Liraglutide Use in Prader-Willi Syndrome

Vancouver General Hospital

Status and phase: Terminated; Phase 4

Conditions: Diabetes Mellitus Type 2; Prader Willi Syndrome

Treatments: Drug: Liraglutide

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01542242

PWS.VGH.UBC

Details and patient eligibility

About

Liraglutide is a glucagon like peptide -1 (GLP-1) agonist, which is approved for use in patients with type 2 diabetes. Studies of liraglutide have shown an appetite suppressive effect and has been associated with weight loss in patients with type 2 diabetes. Liraglutide use in the treatment of PWS is limited to one case report by Cyganek et el (See attached Citation). In this case report, the subject showed improvements in hemoglobin A1c and body weight over 14 weeks.

The investigators plan to examine the use of liraglutide in a single subject with Prader Willi Syndrome and type 2 diabetes for one year. The investigators will examine clinical parameters, clinical assessment of hunger, and biochemical markers of diabetes and lipid control.

Enrollment: 1 patient

Sex: Male

Ages: 19+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Prader Willi Syndrome, Diabetes Type 2

Exclusion criteria

• Previous or family history of Medullary Carcinoma of the Thyroid or multiple endocrine neoplasia syndrome.
• Subjects with acute or chronic Pancreatitis

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1 participants in 1 patient group

Liraglutide

Experimental group

Description:

Treatment of Diabetes Mellitus Type 2 with Liraglutide in the setting of Prader Willi Syndrome

Treatment:

Drug: Liraglutide